Patents
Literature
Patsnap Eureka AI that helps you search prior art, draft patents, and assess FTO risks, powered by patent and scientific literature data.

39 results about "Metabolic derangement" patented technology

The software calculates rates for three PSIs (Postoperative Hemorrhage or Hematoma, Physiologic and Metabolic Derangement, and Respiratory Failure); however, as they were not officially endorsed by the NQF at the time the composite was developed, it excludes them from the composite by assigning them zero weights.

Combination of micronutrients to stimulate the endogenous production of hydrogen sulfide (H2S)

The present invention relates to pharmaceutical, dietary and / or food compositions exerting the ability to activate the endogenous production of hydrogen sulfide (H2S) so to feed the redox buffer capacity and to boost the natural ability to compensate both oxidative and reductive stress.The invention further relates to the use of the aforementioned compositions to correct signs of metabolic derangements such as: oxy-redox imbalances including reductive stress, mitochondrial dysfunction and bioenergetics, insulin resistance, endothelial dysfunction and hyperhomocysteinemia. Accordingly, the composition of the present invention can be used as a medicament for the treatment of hypertension, atherosclerosis and cardiovascular disease, erectile dysfunction, viral infections and inflammatory lung injuries, diabetes and PCOS, autoimmune diseases, neurodegeneration, repeated implantation failure and repeated miscarriage and infertility in both men and women.
Owner:PARTHENOGEN SAGL

Method for improving skeletal health

PendingUS20260076943A1Organic active ingredientsMuscular disorderMetabolic derangementMuscle strength
The present disclosure relates to an alternative intervention to improve skeletal muscle health in chronic kidney disease (CKD). CKD causes skeletal muscle complications that lead to increased risk of falls, hospitalizations and mortality. While exercise is a common treatment for these impairments in the general population, in patients with CKD exercise has shown only marginal improvements in aerobic capacity and inconsistent effects on muscle strength, walking distance, and timed-up-and-go tests indicating this ‘usual’ treatment is not enough in patients in CKD. The present disclosure relates to methods of using an aminoindazole to treat inflammation and metabolic derangements and to improve skeletal muscle health in CKD.
Owner:THE TRUSTEES OF INDIANA UNIV